- ￥1180 - 2800
- 博尔森生物
- BES2R16642
- 中国/上海
- 2025年10月29日
- ELISA
- Rabbit
- 详见操作说明
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
上海博尔森生物科技有限公司
- 库存：
大量
- 靶点：
详见操作说明
- 级别：
详见操作说明
- 克隆性：
多克隆
- 抗原来源：
Rabbit
- 保质期：
12个月
- 抗体英文名：
Influenza A H1N1 Neuraminidase Rabbit pAb
- 抗体名：
A型H1N1流感病毒神经氨酸酶抗体
- 标记物：
详见操作说明
- 宿主：
Rabbit
- 适应物种：
详见操作说明
- 免疫原：
KLH conjugated synthetic peptide derived from Influenza A H1N1 Neuraminidase : 201-300/470
- 亚型：
IgG
- 形态：
液体
- 应用范围：
ELISA
- 保存条件：
Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
- 浓度：
1mg/ml
- 规格：
50ul/100ul/200ul
| 规格： | 50ul | 产品价格： | ￥1180.0 |
|---|---|---|---|
| 规格： | 100ul | 产品价格： | ￥1980.0 |
| 规格： | 200ul | 产品价格： | ￥2800.0 |
Influenza A H1N1 Neuraminidase
Rabbit pAbHost: Rabbit
Isotype: IgG
Clonality: Polyclonal
Target: Influenza A H1N1 Neuraminidase
Immunogen: KLH conjugated synthetic peptide derived from Influenza A H1N1
Neuraminidase: 201-300/470.
Purification: affinity purified by Protein A
Concentration: 1mg/ml
Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles.
Background: Influenza A virus is a major public health threat. Novel influenza virus strains caused by genetic drift and viral recombination emerge periodically to which humans have little or no immunity, resulting in devastating pandemics. Influenza A can exist in a variety of animals; however it is in birds that all subtypes can be found. These subtypes are classified based on the combination of the virus coat glycoproteins hemagglutinin (HA) and neuraminidase (NA) subtypes. During 1997, an H5N1 avian influenza virus was determined to be the cause of death in 6 of 18 infected patients in Hong Kong. There was some evidence of human to human spread of this virus, but it is thought that the transmission efficiency was fairly low. HA interacts with cell surface proteins containing oligosaccharides with terminal sialyl residues.
Virus isolated from a human infected with the H5N1 strain in 1997 could bind to oligosaccharides from human as well as avian sources, ndicating its species jumping ability.
特别提示：本公司的所有产品仅可用于科研实验，严禁用于临床医疗及其他非科研用途！以实际收货产品说明书为准，网站说明书仅供参考。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Neuraminidase inhibitors (NAIs) are presently the only effective antiviral drugs for treatment and chemoprophylaxis of influenza A and B infections, due to the high prevalence of resistance to the adamantane class of drugs among influenza
PCR for the Detection of Influenza Viruses in Clinical Material
). Influenza A viruses are further divided into subtypes H1N1, H2N2 and H3N2, based on differences in the hemagglutinin (HA) and neuraminidase (NA) genes. The ability of influenza viruses to undergo antigenic change in HA and NA enables the virus to evade
Genetic Engineering of Live Attenuated Influenza Viruses
The first live attenuated influenza vaccine (LAIV) was licensed in the USA in 2003; it is a trivalent vaccine composed of two type A (H1N1 and H3N2) and one type B influenza virus each at 107 fluorescent focus units (FFU). Each influenza
